US$3,500.00
Jun 2010
Gastrointestinal Disorder Therapeutics to 2016
GBI Research's report, “Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets”, provides in-depth analysis of the unmet needs, drivers and barriers that affect the global gastrointestinal disorder therapeutics market. It analyzes the markets for gastrointestinal disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
Order Now
|
More Information
|
Tell-a-Friend
US$2,000.00
May 2010
Stomach Cancer - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData’s pharmaceutical and healthcare report, “Stomach Cancer - Drug Pipeline Analysis and Market Forecasts to 2016”, is an essential source of information and analysis on the global stomach cancer market. The report identifies the key trends shaping and driving the global stomach cancer market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products in the global stomach cancer segment.
Order Now |
More Information |
Tell-a-Friend
US$2,000.00
Apr 2010
Nonalcoholic Steatohepatitis - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData's report, “Nonalcoholic Steatohepatitis (NASH)– Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders.
Order Now |
More Information |
Tell-a-Friend
US$2,000.00
Apr 2010
Gastroesophageal Reflux Disease - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData, the industry analysis specialist’s new report, “Gastroesophageal Reflux Disease (GERD) – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global gastroesophageal reflux disease market. The report identifies the key trends shaping and driving the global gastroesophageal reflux disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global gastroesophageal reflux disease sector.
Order Now |
More Information |
Tell-a-Friend
US$2,000.00
Apr 2010
Irritable Bowel Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData, the industry analysis specialist’s new report, “Irritable Bowel Syndrome – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global irritable bowel syndrome market. The report identifies the key trends shaping and driving the global irritable bowel syndrome market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global irritable bowel syndrome sector.
Order Now |
More Information |
Tell-a-Friend
US$2,224.00
Mar 2010
Inflammatory Bowel Disease: World Market 2010-2025
Our new report examines current and future prospects for the inflammatory bowel disease (IBD) drug market. The global market for IBD drugs exceeded $5bn in 2009, with strong growth from the previous year. We predict that the overall market for IBD drugs will expand from 2010 onwards. Main commercial drivers will be disease prevalence, improving diagnosis and wider access to treatments. Currently, IBD is under-diagnosed, especially in developing countries. As governments and other healthcare providers address chronic illnesses like IBD, this market will expand in many countries.
Order Now |
More Information |
Tell-a-Friend
US$3,450.00
Feb 2010
Prebiotics
This report analyzes the US And European markets for Prebiotics in Metric Tons and US$ Million. The US market is further analyzed by the following product segments: Mannan-Oligosaccharide (MOS), Fructans (Fructo-Oligosaccaride (FOS), Inulin), and Others. Annual forecasts are provided for the period 2006 through 2015.
Order Now |
More Information |
Tell-a-Friend
US$4,850.00
Sep 2009
Gastrointestinal Pharmaceuticals: Technologies and Markets
REPORT HIGHLIGHTS
- Overall sales in the gastrointestinal disorder treatment market amounted to $34.2 billionin 2007, and decreased slightly to $31.1 billion in 2009. By 2014, they are projected to reach $32.2 billion, for a 5-year compound annual growth rate (CAGR) of 0.7%.
- The largest segment of the market, prescription gastrointestinal drugs, was valued at $27.4 billion in 2008; this is expected to decrease to $26,3 billion in 2009, and to reach $27 billion in 2014, for a 5-year CAGR of 0.5%.
Order Now |
More Information |
Tell-a-Friend
US$1,495.00
Jul 2009
Acidity - Therapy Area Pipeline Report
Life Science Analytics', Digestive System Acidity contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of acidity drugs by company and by stage as well as a summary of the latest news and developments in this area.
Order Now |
More Information |
Tell-a-Friend
US$1,495.00
Jul 2009
Ulcers - Therapy Area Pipeline Report
Life Science Analytics', Digestive System Ulcers contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of ulcers drugs by company and by stage as well as a summary of the latest news and developments in this area.
Order Now |
More Information |
Tell-a-Friend
US$2,224.00
Oct 2008
World Gastrointestinal Disorders Market 2008-2023
The gastrointestinal (GI) disorders market has been one of the largest and most profitable therapeutic areas in the world pharmaceutical industry. With a reported $49.9bn in revenues in 2007, the GI disorders market competes consistently with cardiovascular diseases and oncology for the top 3 therapeutic areas in terms of market value. In 2007, this sector contributed seven blockbuster drugs, four of which ranked among the top 20 highest revenue generating prescription drugs in the world. However. the market is now mature, with well-established treatments now nearing the end of their patent life. So can you and your company continue to benefit from this market? Are you in a position to capture new profitable shares of the market?
Order Now |
More Information |
Tell-a-Friend
